Related Experiment Video

Updated: Feb 13, 2026

A High-content Assay for Monitoring AMPA Receptor Trafficking
10:34

A High-content Assay for Monitoring AMPA Receptor Trafficking

Published on: January 28, 2019

8.1K

AMPA Receptor Antagonist CFM-2 Decreases Survivin Expression in Cancer Cells

Domingo Sanchez Ruiz1, Hella Luksch2, Marco Sifringer3

  • 1Memory Clinic of Fundacio ACE, Institut Catala de Neurciencies Aplicades, C/Marques de Sentmenat, 57-08029 Barcelona, Spain.

Anti-Cancer Agents in Medicinal Chemistry
|March 2, 2018
PubMed
Abstract

Insights

AMPA receptor antagonists, like CFM-2, show promise in cancer treatment by inhibiting survivin expression, a protein crucial for cancer cell survival and proliferation. This mechanism offers a new strategy for anticancer therapies.

Area of Science:

  • Oncology
  • Neuroscience
  • Molecular Biology

Background:

  • Glutamate receptors, including alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors, are prevalent in various cancer cells.
  • AMPA receptors influence cancer cell signaling pathways involved in survival, proliferation, and migration.
  • Blocking AMPA receptors presents a potential therapeutic strategy for cancer treatment.

Purpose of the Study:

  • To investigate the effect of the AMPA receptor antagonist CFM-2 on survivin expression in cancer cells.
  • To determine if survivin expression influences the efficacy of CFM-2 as an anticancer agent.

Main Methods:

  • Treatment of cancer cells with CFM-2, an AMPA receptor antagonist.
  • Analysis of survivin expression at both mRNA and protein levels.
  • Assessment of cancer cell viability and growth inhibition.
  • Utilizing a cancer cell line engineered to overexpress survivin.

Main Results:

  • CFM-2 significantly inhibits survivin expression at both mRNA and protein levels.
  • CFM-2 treatment leads to a decrease in cancer cell viability.
  • Overexpression of survivin enhances cancer cell viability and reduces the inhibitory effect of CFM-2 on cell growth.

Conclusions:

  • Suppression of survivin expression is identified as a novel mechanism underlying the anticancer effects of AMPA receptor antagonists.
  • AMPA receptor antagonists, exemplified by CFM-2, represent a promising therapeutic avenue for targeting cancer cell survival mechanisms.
Keywords:
AMPA glutamate receptorCFM-2antagonistcancercellsionotropic glutamate receptorssurvivin.

More Related Videos

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.5K
Assaying Surface Expression of Chemosensory Receptors in Heterologous Cells04:55

Assaying Surface Expression of Chemosensory Receptors in Heterologous Cells

Published on: February 23, 2011

11.3K

Related Concept Videos

Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
5.1K
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
1.8K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.3K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.4K
Decreasing Function01:27

Decreasing Function

A decreasing function describes a relationship where the output consistently declines as the input increases. This means that for any two input values, if one is greater than the other, the corresponding output is smaller. Mathematically, a function f is decreasing on an interval I if for every x1 < x2​ in I, f (x1) > f (x2). This type of behavior is visually identified on a graph that slopes downward from left to right.The nature of a function can be analyzed by calculating...
312
Adrenergic Antagonists: Pharmacological Actions of &#593;-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.7K